Search Results - "Pagliaro, L.C."

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies by Matrana, M.R, Duran, C, Shetty, A, Xiao, L, Atkinson, B.J, Corn, P, Pagliaro, L.C, Millikan, R.E, Charnsangave, C, Jonasch, E, Tannir, N.M

“…Abstract Aim The multi-tyrosine kinase inhibitor pazopanib prolongs progression-free survival (PFS) versus placebo in treatment-naive and cytokine-refractory…”
Get full text

Phase II Evaluation Of Stereotactic Ablative Radiotherapy (SABR) in 11C-Choline PET/CT (Cho-PET)-Identified Oligometastatic Castration-Resistant Prostate Cancer (CRPC) by Park, S.S., Abraha, F., Stish, B.J., Lowe, V.J., Pagliaro, L.C., Choo, C.R., Brinkmann, D.H., Iott, M.J., Davis, B.J., Quevedo, F.J., Harmsen, W.S., Costello, B.A., Johnson, G.B., Nathan, M.A., Dong, H., Olivier, K., Pisansky, T.M., Kwon, E.D.

Get full text

Penile cancer: current therapy and future directions by Sonpavde, G., Pagliaro, L.C., Buonerba, C., Dorff, T.B., Lee, R.J., Di Lorenzo, G.

“…Penile cancer (PC) is a rare cancer in western countries, but is more common in parts of the developing world. Due to its rarity and the consequent lack of…”
Get full text

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy by Richey, S.L., Culp, S.H., Jonasch, E., Corn, P.G., Pagliaro, L.C., Tamboli, P., Patel, K.K., Matin, S.F., Wood, C.G., Tannir, N.M.

“…Cytoreductive nephrectomy (CN) became a standard procedure in metastatic renal cell carcinoma (mRCC) in the immunotherapy era. Historically, median overall…”
Get full text

625 THE SPECIFIC CLINICAL CHARACTERISTICS OF DUCTAL PROSTATE CANCER by Leibovici, D, Tu, S.M, Lopez, A, Pagliaro, L.C, Kuban, D.A, Logothetis, C.J, Pisters, L.L

Get full text

Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer by Zurita, A J, Pisters, L L, Wang, X, Troncoso, P, Dieringer, P, Ward, J F, Davis, J W, Pettaway, C A, Logothetis, C J, Pagliaro, L C

“…Background: Prostate cancer persisting in the primary site after systemic therapy may contribute to emergence of resistance and progression. We previously…”
Get full text